Celltrans Inc.

Chicago, IL

UEI
F7W5E7JC53N7
CAGE
7RVG6
Primary NAICS
621511 Medical Laboratories
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
2201 W Campbell Park Dr 217 218, Chicago, IL 60612, USA
Founded
2008
Employees
1-10
Estimated annual revenue
$0-$1M
Industry
  1. Health Care
  2. Health Care Equipment & Services
  3. Health Care Providers & Services
  4. Health Care Services
SIC code
80 Health Services

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant subawards

Prime recipient Prime award Amount Awarded
William Marsh Rice University THOR: Targeted Hybrid Oncotherapeutic Regulation AY1AX000003 $364,620
William Marsh Rice University THOR: Targeted Hybrid Oncotherapeutic Regulation AY1AX000003 $257,106
William Marsh Rice University THOR: Targeted Hybrid Oncotherapeutic Regulation AY1AX000003 $97,132
William Marsh Rice University THOR: Targeted Hybrid Oncotherapeutic Regulation AY1AX000003 $247,298

Similar vendors

Vendor Location Primary NAICS
Exomira Medicine Inc. UEI NPQUP274QX75 Chicago, IL —
Nanocytomics LLC UEI U4RAHVD6K3D8 Northbrook, IL —
Chabad Of California UEI JSNEFFTFMKK5 Los Angeles, CA —
( Formely : American Spanish Institute) UEI TG1JTZZK3BP8 Chicago, IL 624120 Services for the Elderly and Persons with Disabilities
El Paso County Medical Society Foundation UEI GMGYT535MKQ7 Colorado Springs, CO 813219 Other Grantmaking and Giving Services

About the company

Celltrans Inc., a Chicago-based for-profit corporation, operates exclusively as a federal grant sub-recipient, with no prime contract or grant awards in the source record. The vendor has received four sub-awards totaling $966 thousand from the National Institutes of Health, all routed through William Marsh Rice University as the prime recipient under the THOR (Targeted Hybrid Oncotherapeutic Regulation) federal grant program.

Celltrans's entire federal footprint centers on a single grant program and prime relationship. All four sub-awards — dated December 2024, October 2025, March 2026, and March 2026 — flow from the THOR initiative under the Department of Health and Human Services. The combined obligation across all awards stands at $966 thousand. The vendor has not competed for federal contracts, IDIQs, or GWACs, and does not hold a seat on any government-wide vehicles. Activity began in late 2024 and shows two awards in 2026, though the source does not provide award amounts per sub-award, capability descriptions, or details of the work performed under THOR. The vendor's federal footprint is nascent and narrowly concentrated — a single grantor agency, a single prime-recipient partner, and a single grant program — with no diversification across customer agencies, vehicle types, or program lines visible in the source record.

Quick answers

Is Celltrans Inc. registered in SAM.gov?

Yes. Celltrans Inc.'s SAM.gov registration is active through September 15, 2027.

On GovTribe

See Celltrans Inc.'s full federal record

  • Similar vendors